{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:39:00Z","timestamp":1770741540698,"version":"3.49.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>This study aimed to investigate the impact of angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on 3-year clinical outcomes in acute myocardial infarction (AMI) patients without a history of hypertension who underwent successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES). A total of 13,104 AMI patients who were registered in the Korea AMI registry (KAMIR)-National Institutes of Health (NIH) were included in the study. The primary endpoint was 3-year major adverse cardiac events (MACE), which was defined as the composite of all-cause death, recurrent myocardial infarction (MI), and any repeat revascularization. To adjust baseline potential confounders, an inverse probability weighting (IPTW) analysis was performed. The patients were divided into two groups: the ACEI group, n = 4,053 patients and the ARB group, n = 4,107 patients. During the 3-year clinical follow-up, the cumulative incidences of MACE (hazard ratio [HR], 0.843; 95% confidence interval [CI], 0.740\u20130.960; p = 0.010), any repeat revascularization (HR, 0.856; 95% CI, 0.736\u20130.995; p = 0.044), stroke (HR, 0.613; 95% CI, 0.417\u20130.901; p = 0.013), and re-hospitalization due to heart failure (HF) (HR, 0.399; 95% CI, 0.294\u20130.541; p &lt;0.001) in the ACEI group were significantly lower than in the ARB group. In Korean patients with AMI without a history of hypertension, the use of ACEI was significantly associated with reduced incidences of MACE, any repeat revascularization, stroke, and re-hospitalization due to HF than those with the use of ARB.<\/jats:p>","DOI":"10.1371\/journal.pone.0242314","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T13:37:12Z","timestamp":1606743432000},"page":"e0242314","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension"],"prefix":"10.1371","volume":"15","author":[{"given":"Ae-Young","family":"Her","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Geol","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-9852","authenticated-orcid":true,"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-3598","authenticated-orcid":true,"given":"Yong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Ung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"pone.0242314.ref001","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/hrt.2009.188607","article-title":"The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction","volume":"96","author":"P Bramlage","year":"2010","journal-title":"Heart"},{"key":"pone.0242314.ref002","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/2047487318808638","article-title":"Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry","volume":"26","author":"V Tea","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"pone.0242314.ref003","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"B Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"pone.0242314.ref004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"S Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"pone.0242314.ref005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"M Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"pone.0242314.ref006","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"MA Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"pone.0242314.ref007","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"MA Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"pone.0242314.ref008","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"J McMurray","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"pone.0242314.ref009","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0895-7061(99)00042-4","article-title":"Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation","volume":"12","author":"C Borghi","year":"1999","journal-title":"Am J Hypertens"},{"key":"pone.0242314.ref010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00004872-199715070-00012","article-title":"Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event","volume":"15","author":"F Gustafsson","year":"1997","journal-title":"J Hypertens"},{"key":"pone.0242314.ref011","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/eurheartj\/ehr400","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials","volume":"33","author":"FA McAlister","year":"2012","journal-title":"Eur Heart J"},{"key":"pone.0242314.ref012","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"S Yusuf","year":"2004","journal-title":"Lancet"},{"key":"pone.0242314.ref013","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jama.2011.250","article-title":"Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis","volume":"305","author":"AM Thompson","year":"2011","journal-title":"JAMA"},{"key":"pone.0242314.ref014","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijcard.2017.08.030","article-title":"Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"249","author":"SY Choi","year":"2017","journal-title":"Int J Cardiol"},{"key":"pone.0242314.ref015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2018.08.038","article-title":"Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention","volume":"277","author":"JK Byun","year":"2018","journal-title":"Atherosclerosis"},{"key":"pone.0242314.ref016","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/bmj.326.7399.1137","article-title":"ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure","volume":"326","author":"ED Grech","year":"2003","journal-title":"BMJ"},{"key":"pone.0242314.ref017","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.116.025950","article-title":"Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction","volume":"135","author":"FH Messerli","year":"2017","journal-title":"Circulation"},{"key":"pone.0242314.ref018","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"MH Strauss","year":"2006","journal-title":"Circulation"},{"key":"pone.0242314.ref019","doi-asserted-by":"crossref","first-page":"183.e111","DOI":"10.1016\/j.amjmed.2009.06.032","article-title":"Angiotensin-converting enzyme-related cough among Chinese-Americans","volume":"123","author":"DS Tseng","year":"2010","journal-title":"Am J Med"},{"key":"pone.0242314.ref020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40256-015-0140-5","article-title":"Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry","volume":"15","author":"PS Song","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"pone.0242314.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2014.03.055","article-title":"Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker","volume":"114","author":"M Hara","year":"2014","journal-title":"Am J Cardiol"},{"key":"pone.0242314.ref022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0003319719884187","article-title":"ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents","volume":"71","author":"YH Kim","year":"2020","journal-title":"Angiology"},{"key":"pone.0242314.ref023","first-page":"253","article-title":"Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","author":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","year":"2000","journal-title":"Lancet"},{"key":"pone.0242314.ref024","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"key":"pone.0242314.ref025","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"KM Fox","year":"2003","journal-title":"Lancet"},{"key":"pone.0242314.ref026","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1056\/NEJMoa041905","article-title":"Coronary-artery revascularization before elective major vascular surgery","volume":"351","author":"EO McFalls","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0242314.ref027","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJM200503033520919","article-title":"ACE inhibition in stable coronary artery disease","volume":"352","author":"S Yusuf","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0242314.ref028","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","article-title":"Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox","volume":"135","author":"MH Strauss","year":"2017","journal-title":"Circulation"},{"key":"pone.0242314.ref029","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"F Turnbull","year":"2003","journal-title":"Lancet"},{"key":"pone.0242314.ref030","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"S Julius","year":"2004","journal-title":"Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0242314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T13:37:19Z","timestamp":1606743439000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0242314"}},"subtitle":[],"editor":[{"given":"Timir","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0242314","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}